Abstract
Many radiopharmaceuticals have been successfully used in nuclear medicine to detect neuroendocrine tumors, and many of them are based on a specific mechanism of uptake, while others are non-specific probes. This "review" focuses on the clinical applications of metaiodobenzylguanidine, (111)In-pentreotide and positron emission tomography (PET) tracers. New avances in diagnostic imaging will be discussed. Molecular imaging serves these diagnostic functions and provides powerful means for non-invasively detecting disease.
MeSH terms
-
3-Iodobenzylguanidine / pharmacokinetics
-
Adrenal Gland Neoplasms / diagnostic imaging
-
Biomarkers, Tumor / analysis
-
Carcinoma, Medullary / diagnostic imaging
-
Gastrointestinal Neoplasms / diagnostic imaging
-
Humans
-
Iodine Radioisotopes
-
Neuroendocrine Tumors / chemistry
-
Neuroendocrine Tumors / diagnostic imaging*
-
Pheochromocytoma / diagnostic imaging
-
Positron-Emission Tomography / methods*
-
Radiopharmaceuticals* / pharmacokinetics
-
Receptors, Somatostatin / analysis
-
Sensitivity and Specificity
-
Somatostatin / analogs & derivatives*
-
Somatostatin / pharmacokinetics
-
Somatostatin / physiology
-
Thyroid Neoplasms / diagnostic imaging
-
Tomography, Emission-Computed, Single-Photon / methods
Substances
-
Biomarkers, Tumor
-
Iodine Radioisotopes
-
Radiopharmaceuticals
-
Receptors, Somatostatin
-
3-Iodobenzylguanidine
-
Somatostatin
-
pentetreotide